Showing 1491-1500 of 2173 results for "".
- FDA Says No to Evolus' Botox Rivalhttps://modernaesthetics.com/news/fda-says-no-to-evolus-botox-rival/2472089/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more
- Early Botox May Improve Surgical Scarshttps://modernaesthetics.com/news/early-botox-may-improve-surgical-scars/2472124/Early injections of botulinum toxin A can improve the final appearance of surgical scars, according to a study in the March issue of Plastic
- Cynosure's TempSure™ Envi Set to Debut at 2018 AAD Meetinghttps://modernaesthetics.com/news/cynosures-tempsure-envi-set-to-debut-at-2018-aad-meeting/2472144/Hologic's Cynosure division is launching TempSure™ Envi – an FDA-cleared advanced radiofrequency device. TempSure™ Envi heats the deep layers of skin to regenerate collagen and
- Sciton Launches diVa® Center of Excellence Programhttps://modernaesthetics.com/news/sciton-launches-diva-center-of-excellence-program/2472230/Sciton, Inc.’s new diVa® Center of Excellence Program will spotlight urogynecologists, urologists, OB/GYN's and gynecologists who are dedicated to creating an optimal Treatment Experience for women. The Centers will review data and outcome
- Juvéderm Vollure XC FDA Approved for Correction of Facial Wrinkles and Foldshttps://modernaesthetics.com/news/juvderm-vollure-xc-fda-approved-for-correction-of-facial-wrinkles-and-folds/2472255/The FDA has approved Allergan plc's Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. In the US pivotal clinical trial, a majority (59 percent) of subjects saw improvement in moderate to severe na
- Deadline Extended for Medical Spa State of the Industry Statistical Studyhttps://modernaesthetics.com/news/deadline-extended-for-medical-spa-state-of-the-industry-statistical-study/2472272/The American Med Spa Association (AmSpa) has extended the deadline for the 2017 Medical Spa St
- Allergan Launches Juvéderm Volitehttps://modernaesthetics.com/news/allergan-launches-juvderm-volite/2472287/Allergan plc launched Juvéderm Volite, an injectable product specifically designed to improve skin quality and last up to nine months with just one treatment session. This innovative new Allergan product uses the unique patented Vycross technology. The new HA injectable treatment d
- Imaging Study Explores Tissue Repair Dynamics After UltraClear Laser Therapyhttps://modernaesthetics.com/news/imaging-study-explores-tissue-repair-dynamics-after-ultraclear-laser-therapy/2487167/Serial line-field confocal optical coherence tomography (LC-OCT) imaging may provide a noninvasive method for visualizing tissue repair following laser-coring procedures, according to findings published in Lasers in Surgery and Medicine.1 In the technical demonstration
- Interim IIT Data Explore Sculptra, Restylane for Menopause, Weight Loss–Related Aesthetic Changeshttps://modernaesthetics.com/news/interim-iit-data-explore-sculptra-restylane-for-menopause-weight-lossrelated-aesthetic-changes/2486595/Interim findings from 2 ongoing investigator-initiated trials supported by Galderma suggest potential roles for Sculptra and the Restylane portfolio in treating aesthetic changes associated with menopause and medication-driven weight loss. In one interim analysis led by Sabrina Fabi, MD, 2
- Lynch Regenerative Medicine Expands PDGF Portfolio With GEM 21S® Distribution Agreementhttps://modernaesthetics.com/news/lynch-regenerative-medicine-expands-pdgf-portfolio-with-gem-21s-distribution-agreement/2486379/Lynch Regenerative Medicine, LLC (LRM) announced a definitive distribution agreement with Lynch Biologics, a Geistlich North America company, to commercialize GEM 21S®, an FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB) product, to licensed healthcare providers in the Un